M&A / Deals AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid Pharmaceutical TechnologyAbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.M&A / DealsPain & AnaesthesiaRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries. M&A / DealsPain & AnaesthesiaRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: AbbVie enters world of pain in up to $715M deal with China’s Haisco Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
